Suppr超能文献

了解参与一项IIb期HIV疫苗试验的高危人群在入组结果方面的差异。

Understanding differences in enrollment outcomes among high-risk populations recruited to a phase IIb HIV vaccine trial.

作者信息

Frew Paula M, del Rio Carlos, Lu Lu, Clifton Sarah, Mulligan Mark J

机构信息

Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA.

出版信息

J Acquir Immune Defic Syndr. 2009 Mar 1;50(3):314-9. doi: 10.1097/QAI.0b013e3181945eec.

Abstract

BACKGROUND

The Step Study, a Phase IIb HIV vaccine proof of concept study, enrolled approximately 3000 persons in clade B regions. The Atlanta site sought to enroll a diverse population. This prospective cohort study examined key factors associated with participant enrollment.

METHODS

We obtained participant information (eg, sociodemographic, medical) and followed outcomes from 2005 to 2007. Of the 810 potential "Step Study" participants, 340 cases were analyzed.

RESULTS

The recruitment strategy generated strong interest among minorities with 37% eligible after prescreening, yet 25% of the minorities enrolled. However, the percentage of whites increased from 62% eligible (prescreened sample) to 75% enrolled. The regression model was significant with educational level being an enrollment predictor (P = 0.0023). Those with at least a bachelor's degree were more likely to enroll compared with those with a K-12 education or some college (odds ratio = 2.424, 95% confidence interval = 1.372 to 4.281, P < 0.01). White race was also a significant factor (odds ratio = 2.330; 95% confidence interval = 1.241 to 4.375, P < 0.01). No difference in enrollment was observed among recruitment approaches, Pearson chi (2) (n = 336) = 5.286, P = 0.07.

CONCLUSIONS

The results from this study indicate that women, minorities, and those with lower educational attainment were less likely to enroll in an HIV vaccine efficacy study at our site. The findings highlight an important consideration on the role of health literacy to sustain participation of eligible minorities in HIV vaccine trials.

摘要

背景

“Step研究”是一项IIb期HIV疫苗概念验证研究,在B亚型区域招募了约3000人。亚特兰大研究点试图招募多样化的人群。这项前瞻性队列研究调查了与参与者入组相关的关键因素。

方法

我们获取了参与者信息(如社会人口统计学、医学信息),并追踪了2005年至2007年的结果。在810名潜在的“Step研究”参与者中,分析了340例。

结果

招募策略在少数族裔中引起了强烈兴趣,预筛选后37%符合条件,但只有25%的少数族裔入组。然而,白人的比例从符合条件的62%(预筛选样本)增至入组的75%。回归模型具有显著性,教育水平是入组的一个预测因素(P = 0.0023)。与接受K-12教育或上过一些大学的人相比,至少拥有学士学位的人更有可能入组(优势比 = 2.424,95%置信区间 = 1.372至4.281,P < 0.01)。白人种族也是一个显著因素(优势比 = 2.330;95%置信区间 = 1.241至4.375,P < 0.01)。在不同招募方法之间未观察到入组差异,Pearson卡方检验(n = 336)= 5.286,P = 0.07。

结论

本研究结果表明,女性、少数族裔以及教育程度较低的人在我们研究点参与HIV疫苗疗效研究的可能性较小。这些发现凸显了健康素养在使符合条件的少数族裔持续参与HIV疫苗试验方面作用的一个重要考量因素。

相似文献

1
Understanding differences in enrollment outcomes among high-risk populations recruited to a phase IIb HIV vaccine trial.
J Acquir Immune Defic Syndr. 2009 Mar 1;50(3):314-9. doi: 10.1097/QAI.0b013e3181945eec.
2
Representation of Latinos and Blacks in screening for and enrollment into preventive HIV vaccine trials in New York City.
Vaccine. 2015 Nov 27;33(48):6809-15. doi: 10.1016/j.vaccine.2015.09.091. Epub 2015 Oct 11.
4
Motivation, recruitment, and screening of volunteers for a phase I/II HIV preventive vaccine trial in Thailand.
J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Jun 1;18(2):171-7. doi: 10.1097/00042560-199806010-00009.
5
Feasibility of a preventive HIV-1 vaccine cohort among persons attending sexually transmitted disease clinics in Thailand.
J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Apr 15;20(5):488-94. doi: 10.1097/00042560-199904150-00012.
6
Willingness to participate and enroll in a phase 3 preventive HIV-1 vaccine trial.
J Acquir Immune Defic Syndr. 2002 Dec 15;31(5):521-8. doi: 10.1097/00126334-200212150-00010.

引用本文的文献

1
Representation of Latinos and Blacks in screening for and enrollment into preventive HIV vaccine trials in New York City.
Vaccine. 2015 Nov 27;33(48):6809-15. doi: 10.1016/j.vaccine.2015.09.091. Epub 2015 Oct 11.
3
Experiences in recruiting volunteers through community based initiatives in phase-1 vaccine trials in India.
Hum Vaccin Immunother. 2014;10(2):485-91. doi: 10.4161/hv.26799. Epub 2013 Oct 18.
5
Who participates in internet-based worksite weight loss programs?
BMC Public Health. 2011 Sep 20;11:709. doi: 10.1186/1471-2458-11-709.
6
Conceptual framework for behavioral and social science in HIV vaccine clinical research.
Vaccine. 2011 Oct 13;29(44):7794-800. doi: 10.1016/j.vaccine.2011.07.108. Epub 2011 Aug 5.
7
Selectively willing and conditionally able: HIV vaccine trial participation among women at "high risk" of HIV infection.
Vaccine. 2011 Aug 18;29(36):6130-5. doi: 10.1016/j.vaccine.2011.06.064. Epub 2011 Jun 23.
8
9
The likelihood of participation in clinical trials can be measured: the Clinical Research Involvement Scales.
J Clin Epidemiol. 2010 Oct;63(10):1110-7. doi: 10.1016/j.jclinepi.2009.12.002. Epub 2010 Mar 19.

本文引用的文献

2
Estimation of HIV incidence in the United States.
JAMA. 2008 Aug 6;300(5):520-9. doi: 10.1001/jama.300.5.520.
3
Negative social impacts among volunteers in an HIV vaccine efficacy trial.
J Acquir Immune Defic Syndr. 2007 Nov 1;46(3):362-8. doi: 10.1097/QAI.0b013e3181565dcb.
4
Why blacks do not take part in HIV vaccine trials.
J Natl Med Assoc. 2007 Mar;99(3):254-7.
5
Racial/ethnic disparities in diagnoses of HIV/AIDS--33 states, 2001-2005.
MMWR Morb Mortal Wkly Rep. 2007 Mar 9;56(9):189-93.
6
Willingness to participate in HIV vaccine trials: the impact of trial attributes.
Prev Med. 2007 Jun;44(6):554-7. doi: 10.1016/j.ypmed.2006.12.007. Epub 2006 Dec 24.
7
Enrolling women into HIV preventive vaccine trials: an ethical imperative but a logistical challenge.
PLoS Med. 2006 Mar;3(3):e94. doi: 10.1371/journal.pmed.0030094. Epub 2006 Feb 21.
9
HIV vaccine trial participation among ethnic minority communities: barriers, motivators, and implications for recruitment.
J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):210-7. doi: 10.1097/01.qai.0000179454.93443.60.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验